On this page
TPM1
tropomyosin 1
TPM1 encodes tropomyosin, a structural protein critical for regulating muscle contraction in the heart and skeletal muscle. The TPM1 gene provides instructions for making tropomyosin, a protein that forms part of the contractile apparatus in muscle cells.
TPM1 is located on the long (q) arm of chromosome 15, at band 15q22.2. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 15 in the library →Overview
The TPM1 gene, located on chromosome 15, encodes tropomyosin 1, a fundamental component of the muscle contractile system. Tropomyosin belongs to a family of closely related proteins that bind to actin filaments and regulate muscle contraction by controlling access to myosin binding sites. In cardiac muscle, tropomyosin works in concert with the troponin complex to ensure that contraction occurs only when calcium ions signal the heart to beat.
The gene produces multiple protein isoforms through alternative splicing, with different variants expressed in cardiac muscle, skeletal muscle, and smooth muscle tissues. The cardiac isoform plays an essential role in maintaining normal heart function throughout life. Because tropomyosin is integral to force generation in the heart, alterations in TPM1 can disrupt the delicate balance of muscle contraction and relaxation, leading to structural and functional abnormalities of the cardiac muscle. This gene has been recognised as clinically significant in the context of inherited cardiovascular disease.
What the gene does
Tropomyosin 1 functions as a regulatory protein within the thin filaments of muscle sarcomeres, the basic contractile units of muscle tissue. The protein forms dimers that wind around actin filaments in a head-to-tail arrangement, creating continuous cables that extend along the length of the filament. This positioning allows tropomyosin to physically block or expose myosin-binding sites on actin, thereby controlling whether muscle contraction can occur.
In cardiac muscle, the regulatory mechanism operates through calcium-dependent signalling. When calcium levels rise during the cardiac action potential, calcium ions bind to troponin C, causing a conformational change in the troponin complex. This change shifts the position of tropomyosin on the actin filament, exposing binding sites that allow myosin heads to attach and generate force through cross-bridge cycling. When calcium levels fall, tropomyosin returns to its blocking position, and the muscle relaxes.
The precise positioning and flexibility of tropomyosin are critical for normal cardiac function. The protein must be stable enough to maintain its regulatory role but flexible enough to shift position in response to troponin movement. This dual requirement means that even subtle changes to tropomyosin structure can alter the calcium sensitivity of contraction, the force generated by each heartbeat, or the speed of muscle relaxation. Such changes can lead to either insufficient contractile force, as seen in dilated cardiomyopathy, or excessive contractility and impaired relaxation, characteristic of hypertrophic cardiomyopathy.
Beyond its mechanical role, tropomyosin also contributes to the structural stability of thin filaments and may influence other sarcomeric proteins. The protein helps maintain proper spacing and organisation of actin filaments within the sarcomere, ensuring efficient force transmission. Different tropomyosin isoforms are expressed in a tissue-specific manner, allowing fine-tuning of contractile properties in different muscle types.
Video: Genetics 101
Chromosome location
TPM1 is located on the long arm of chromosome 15 at position 22.2, designated as 15q22.2. The gene spans approximately 33 kilobases of genomic DNA and contains nine exons that encode the cardiac isoform of tropomyosin. Through alternative splicing of these exons, the gene produces multiple distinct protein isoforms that are expressed in different muscle tissues.
The chromosomal region 15q22.2 contains several other genes, but TPM1 is the primary gene in this region associated with inherited cardiac disease. The gene's structure allows for complex regulation of isoform expression, with specific exon combinations determining whether the resulting protein functions in cardiac muscle, fast skeletal muscle, or slow skeletal muscle. The cardiac-specific isoform, known as α-tropomyosin, is the predominant form in the adult human heart.
Protein structure
The TPM1-encoded tropomyosin protein is 284 amino acids in length and adopts an almost entirely alpha-helical structure. The defining structural feature is a coiled coil domain that extends across the full length of the protein from amino acids 1 to 284, forming the basis of tropomyosin's elongated, rod-like shape. This extended coiled coil structure is essential for the protein's function, as it allows tropomyosin to span multiple actin subunits along the thin filament.
Within this overall coiled coil architecture, the protein contains two disordered regions that provide functional flexibility. The first disordered region encompasses amino acids 1 to 38 at the N-terminus, and the second spans amino acids 116 to 136 near the middle of the protein. These disordered regions are thought to contribute to the protein's ability to undergo conformational changes during the regulatory cycle of muscle contraction.
The coiled coil structure is stabilised by a characteristic heptad repeat pattern in the amino acid sequence, where hydrophobic residues at specific positions promote the association of two alpha-helical chains. This structure creates a rigid yet flexible cable that can transmit conformational changes along its length. The head-to-tail assembly of tropomyosin dimers along the actin filament requires precise geometry at the termini, and the N-terminal disordered region may facilitate this assembly process. The central disordered region may act as a hinge point, allowing the molecule to bend slightly in response to troponin-mediated signals.
Key variants
Pathogenic variants in TPM1 have been identified throughout the gene, affecting different aspects of tropomyosin structure and function. Most disease-causing changes are missense variants that alter single amino acids within the coiled coil domain, disrupting either the stability of the tropomyosin dimer or its interactions with actin and troponin. Because the coiled coil structure is critical for tropomyosin's regulatory function, even small changes can have significant effects on muscle contraction.
Variants associated with hypertrophic cardiomyopathy often increase the calcium sensitivity of contraction or enhance the force generated by each heartbeat, leading to excessive muscle thickening over time. In contrast, variants linked to dilated cardiomyopathy typically reduce contractile force or impair the protein's ability to stabilise thin filaments, resulting in chamber enlargement and weakened pumping function. Some variants have been reported in association with left ventricular non-compaction, a condition characterised by abnormal trabeculation of the heart muscle.
The phenotypic consequences of TPM1 variants can vary considerably, even within families carrying the same genetic change. This phenomenon, known as variable or incomplete penetrance, means that not all individuals with a pathogenic variant will develop cardiomyopathy, and the age of onset and severity can vary considerably, even within families carrying the same genetic change. Age of onset, severity of symptoms, and progression of cardiac dysfunction all show considerable heterogeneity among individuals with TPM1-related cardiomyopathy.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.188C>T | p.Ala63Val | Pathogenic/Likely pathogenic | ★★☆☆ | Hypertrophic cardiomyopathy 3 |
c.284T>C | p.Val95Ala | Pathogenic/Likely pathogenic | ★★☆☆ | Cardiovascular phenotype |
c.292G>A | p.Glu98Lys | Pathogenic/Likely pathogenic | ★★☆☆ | Hypertrophic cardiomyopathy 3 |
c.475G>A | p.Asp159Asn | Pathogenic/Likely pathogenic | ★★☆☆ | TPM1-related disorder |
c.479G>A | p.Arg160His | Pathogenic/Likely pathogenic | ★★☆☆ | TPM1-related disorder |
c.523G>A | p.Asp175Asn | Pathogenic | ★★☆☆ | Cardiovascular phenotype |
c.539A>G | p.Glu180Gly | Pathogenic | ★★☆☆ | Hypertrophic cardiomyopathy |
c.574G>A | p.Glu192Lys | Pathogenic/Likely pathogenic | ★★☆☆ | TPM1-related disorder |
c.644C>T | p.Ser215Leu | Pathogenic/Likely pathogenic | ★★☆☆ | Cardiovascular phenotype |
c.688G>A | p.Asp230Asn | Pathogenic | ★★☆☆ | TPM1-related disorder |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
TPM1 is included in the American College of Medical Genetics and Genomics (ACMG) Secondary Findings list, version 3.2, as a gene with established clinical actionability. This designation reflects the availability of evidence-based interventions that can reduce morbidity and mortality when pathogenic variants are identified, even in individuals who have not yet developed symptoms.
The primary conditions associated with TPM1 variants are inherited forms of cardiomyopathy, a group of disorders affecting the structure and function of the heart muscle. These conditions follow an autosomal dominant inheritance pattern, meaning a single pathogenic variant is sufficient to cause disease, and affected individuals have a 50% chance of passing the variant to each of their children. Early identification of at-risk family members allows for cardiac surveillance and timely implementation of preventive measures.
No disease links recorded for this gene in our reference set.
Inheritance pattern
Conditions caused by pathogenic TPM1 variants typically follow autosomal dominant inheritance.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
UK clinical status
Within the NHS Genomic Medicine Service in England, TPM1 has been designated a "green" gene on multiple clinical gene panels, indicating strong evidence for its role in specific cardiac conditions. The gene appears on the Hypertrophic Cardiomyopathy panel (R131), the Dilated and Arrhythmogenic Cardiomyopathy panel (R132), and the Paediatric or Syndromic Cardiomyopathy panel (R135), reflecting its relevance across the spectrum of inherited heart muscle disease.
TPM1 is also included on the Dilated Cardiomyopathy and Conduction Defects panel and the Left Ventricular Noncompaction Cardiomyopathy panel. This broad inclusion across multiple panels underscores the gene's importance in the differential diagnosis of unexplained cardiomyopathy presenting in both paediatric and adult populations. Green designation means that genetic testing for TPM1 variants may be appropriate in individuals with relevant clinical presentations, and that results are considered clinically valid for guiding patient management within the NHS.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
For individuals with TPM1-related cardiomyopathy, lifestyle recommendations typically focus on cardiovascular health and avoiding factors that may exacerbate cardiac dysfunction. Research in broader cardiomyopathy populations suggests that moderate physical activity may be beneficial for maintaining overall fitness. Clinical guidelines recommend individualised exercise plans, with competitive or high-intensity sports typically restricted for those with high-risk features such as significant hypertrophy, arrhythmias, or unexplained syncope. Many individuals can engage in moderate recreational activity safely.
Maintaining a healthy body weight and following a balanced diet may help reduce additional strain on the heart. Some studies in heart failure populations have suggested that limiting sodium intake may help manage fluid retention, though the evidence for specific dietary interventions in genetic cardiomyopathies remains limited. Alcohol consumption may worsen cardiac function in some individuals with cardiomyopathy, and moderation or avoidance is often recommended.
Stress management and adequate sleep are general measures that may support cardiovascular health. Because some individuals with cardiomyopathy experience arrhythmias, avoiding stimulants such as excessive caffeine may be advisable, though evidence for specific restrictions varies. Lifestyle measures do not replace medical management or regular cardiac monitoring, and individuals with TPM1 variants should work closely with a cardiologist or specialist in inherited cardiac conditions to develop a personalised care plan.
Supplement considerations
No dietary supplement has been shown to prevent, treat, or modify the course of TPM1-related cardiomyopathy. Some individuals with heart failure are prescribed specific supplements such as coenzyme Q10 or L-carnitine as part of their medical regimen, but the evidence base for these interventions in genetic cardiomyopathies is not robust, and their use should be guided by a healthcare professional.
Magnesium and potassium levels are important for normal cardiac electrical activity, and deficiencies of these electrolytes can increase arrhythmia risk in individuals with underlying heart disease. However, supplementation should only be undertaken if blood tests demonstrate deficiency, and excessive intake can be harmful. Omega-3 fatty acids from fish oil have been studied in various cardiovascular conditions, but their specific role in inherited cardiomyopathies has not been definitively established.
Some marketed supplements claim to support "heart health" or "muscle function," but these products have not been rigorously tested in populations with genetic cardiomyopathies, and their safety and efficacy remain uncertain. Before starting any supplement, individuals with TPM1 variants should discuss the decision with their cardiologist or genetic counsellor, as some supplements may interact with prescribed medications or have unintended effects on cardiac function.
Frequently asked questions
What does the TPM1 gene do?
TPM1 provides instructions for making tropomyosin, a protein that regulates muscle contraction by controlling the interaction between actin and myosin filaments in heart and skeletal muscle. In cardiac muscle, tropomyosin works with the troponin complex to ensure that contraction occurs in response to calcium signals.
How is TPM1-related cardiomyopathy inherited?
TPM1-related cardiomyopathy follows an autosomal dominant pattern of inheritance. This means that inheriting one pathogenic variant from either parent is sufficient to increase the risk of developing the condition, and affected individuals have a 50% chance of passing the variant to each of their children.
What types of heart conditions are linked to TPM1 variants?
Pathogenic variants in TPM1 are associated with hypertrophic cardiomyopathy, dilated cardiomyopathy, and left ventricular non-compaction. These conditions involve abnormalities in the structure and function of the heart muscle that can lead to heart failure, arrhythmias, and other complications.
Can TPM1 variants be detected before symptoms appear?
Yes, genetic testing can identify TPM1 variants in individuals before they develop symptoms of cardiomyopathy. Early detection allows for regular cardiac monitoring and, when appropriate, preventive interventions that may reduce the risk of serious complications.
Is genetic testing for TPM1 available through the NHS?
Genetic testing for TPM1 is available through the NHS Genomic Medicine Service for individuals meeting specific clinical criteria, such as a diagnosis of cardiomyopathy or a family history of the condition. Testing is typically arranged by a cardiologist or clinical genetics service.
What should I do if I have a TPM1 variant?
If you have a pathogenic or likely pathogenic variant in TPM1, you should be under the care of a cardiologist with expertise in inherited cardiac conditions. Regular cardiac imaging, lifestyle modifications, and, when appropriate, medications or device therapies can help manage the condition and reduce the risk of complications. Family members may also be offered genetic testing and cardiac screening.